Mirlekar reported that specific deletion of IL-35 in B cells overcame immunotherapy resistance to anti-PD-1 through activation of CD8+ T cells in murine pancreatic cancer model (80). This evidence concerns the gene CD8A and familial pancreatic carcinoma.